In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gennex Laboratories' board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. On a consolidated basis, revenue from operations jumped ~59% YoY to ₹13,790.30 lacs (FY24: ₹8,671.44 lacs), while net profit grew ~37.6% to ₹1,812.49 lacs (FY24: ₹1,317.50 lacs), with EPS at ₹0.797 vs ₹0.666. Standalone revenue rose ~41.6% to ₹9,457.79 lacs and net profit grew ~19% to ₹1,403.68 lacs. However, both standalone and consolidated operating cash flows were negative (₹-955.94 lacs and ₹-1,079.70 lacs respectively). Auditor R Pugalia & Company issued a qualified opinion (repetitive qualification) on unresolved balance confirmations across current assets/liabilities, partial CSR compliance, and pending installation of transaction traceability software. The board also appointed Mr. Sandeep Kumar Daga as Non-Executive Non-Independent Director following the resignation of Dr. S CH Dharma Rao.
Strong top-line and bottom-line growth in FY25 is positive for shareholders, but the repetitive qualified audit opinion and negative operating cash flow raise concerns about balance sheet accuracy and cash quality. Investors should watch for resolution of the auditor's qualifications and improvement in operating cash generation. The director change is routine and not material.